Nanomedicines: from bench to bedside and beyond.

Pharmacokinetics of Pegylated Liposomal Doxorubicin

Gabizón, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,639 · see citing works

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W. C., Farokhzad, O. C., Barry, S. T., Gabizón, A., Grodzinski, P. A., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,493 · see citing works

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

Hrkach, J. S., Hoff, D. D. V., Ali, M. M., Andrianova, E. A., Auer, J., Campbell, T., Witt, D. D., Figa, M. A., Figueiredo, M., Horhota, A. T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147 · see citing works

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

Johnson, J. I., Decker, S., Zaharevitz, D. W., Rubinstein, L., Venditti, J. M., Schepartz, S. A., Kalyandrug, S., Christian, M. C., Arbuck, S. G., Hollingshead, M. G., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856 · see citing works

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575 · see citing works

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Sparreboom, A., Scripture, C. D., Trieu, V. N., Williams, P. J., De, T., Yang, A. J., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 506 · see citing works

Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines

Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 311 · see citing works

Translational value of mouse models in oncology drug development

Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293 · see citing works

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 289 · see citing works

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Ashton, S. E., Song, Y. H., Nolan, J., Cadogan, E. B., Murray, J. A. H., Odedra, R., Foster, J. R., Hall, P. A., Low, S. C., Taylor, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2355 · Cited by 218 · see citing works

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101

Svenson, S., Wolfgang, M., Hwang, J., Ryan, J. L., & Eliasof, S. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.007 · Cited by 153 · see citing works

Molecular Targets and Mechanisms of Cancer Prevention and Treatment by Withaferin A, A Naturally Occurring Steroidal Lactone

Vyas, A. R., & Singh, S. V. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9531-1 · Cited by 132 · see citing works

Liposomal and Nonliposomal Drug Pharmacokinetics after Administration of Liposome-Encapsulated Vincristine and Their Contribution to Drug Tissue Distribution Properties

Krishna, R., Webb, M. S., St.-Onge, G., & Mayer, L. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29494-5 · Cited by 129 · see citing works

Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog

Masini, E., Planchenault, J., Pezziardi, F., Gautier, P., & Gagnol, J. P. (1985) · Inflammation Research · doi:10.1007/bf01983649 · Cited by 107 · see citing works

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology

Ait‐Oudhia, S., Mager, D. E., & Straubinger, R. M. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6010137 · Cited by 93 · see citing works

Delivering nanomedicines to patients: A practical guide

Eaton, M., Lévy, L., & Fontaine, O. M. A. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.02.004 · Cited by 77 · see citing works

Complement activation associated with polysorbate 80 in beagle dogs

Qiu, S., Liu, Z., Hou, L., Li, Y., Wang, J., Wang, H., Du, W., Wang, W., Qin, Y., & Liu, Z. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.021 · Cited by 67 · see citing works

Nanotechnology

Langer, R., & Weissleder, R. (2015) · JAMA · doi:10.1001/jama.2014.16315 · Cited by 62 · see citing works

A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents

Caron, W. P., Morgan, K. P., Zamboni, B. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3649 · Cited by 40 · see citing works

Nanomedicine Drug Development: A Scientific Symposium Entitled “Charting a Roadmap to Commercialization”

Finch, G. L., Havel, H. A., Analoui, M., Barton, R. W., Diwan, A. R., Hennessy, M. G., Reddy, V. R., Sadrieh, N. K., Tamarkin, L., Wolfgang, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9608-5 · Cited by 19 · see citing works

CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products

Cruz, C. N., Tyner, K. M., Velazquez, L., Hyams, K. C., Jacobs, A. C., Shaw, A. B., Jiang, W., Lionberger, R. A., Hinderling, P. H., Kong, Y., et al. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9466-6 · Cited by 18 · see citing works

Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)

Ramanathan, R. K., Korn, R. L., Sachdev, J. C., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct224 · Cited by 17 · see citing works

A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution

Weber, B., Hochhaus, G., Adams, W. P., et al. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9410-1 · Cited by 17 · see citing works

PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients

Hendriks, B. S., Shields, A. F., Siegel, B. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu068.1 · Cited by 10 · see citing works

Abstract 911: Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel

Low, S. C., Hoff, D. D. V., Mita, M. M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-911 · Cited by 2 · see citing works

Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs

Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works

PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up

Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302 · see citing works

The in vivo fate of polymeric micelles

Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154 · see citing works

Nanopharmaceutics: part I-Clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU

Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielinska, A., Ventura, F., Durazzo, A., Lucarini, M., Novellino, E., & Santini, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020146 · Cited by 144 · see citing works

Recent Advances in the Development of Magnetic Nanoparticles for Biomedical Applications

Monteserín, M., Larumbe, S., Martínez, A. V., Burgui, S., & Francisco Martín, L. (2021) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2021.19062 · Cited by 27 · see citing works

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

心不全とサイトカイン : TNF-α過剰発現マウスを用いて(循環器教育セッションII循環器のbench to bedside, bedside to bench)

徹, 久. (2001) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.8.supple_50

心臓とサイトカイン : サイトカインの研究は心疾患の診断・治療に役立つか? (循環器教育セッションII循環器のbench to bedside, bedside to bench)

昭, 松. (2001) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.8.supple_43

冠動脈生検組織における蛋白・遺伝子発現(循環器教育セッションII循環器のbench to bedside, bedside to bench)

真喜子, 上. (2001) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.8.supple_38

Traumatic Brain Injury: From Bench to Bedside to Society

Chen, A. J.-W., & D’Esposito, M. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.041 · Cited by 5 · see citing works